Home > Resources > Whitepapers > The EU5 Market Access Landspace for Oncology Drugs

The EU5 Market Access Landspace for Oncology Drugs

Global sales of oncology medicines were widely reported to have exceeded $100 billion for the first time in 2014, with the U.S. and European markets generating the majority of sales. This trajectory is expected to continue: Decision Resources Group (DRG) analysis suggests sales of oncology medicines will exceed sales of medicines in every other therapeutic area, growing at a nearly double-digit compound annual growth rate through 2021 to reach $170 billion (Figure 1). This surge will be driven by the approval and uptake of targeted small molecules and biologic therapies, reflecting the industry’s shift towards personalized treatments and a wide array of molecular and immunological targets.

Spotlight

Pharma IQ

Pharma IQ, a division of IQPC, is an international online community focusing on providing pharmaceutical professionals with knowledge, information and articles. We are dedicated to creating a learning environment for sharing ideas, best practices and solutions within the pharmaceutical community.

OTHER WHITEPAPERS

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out andsales force routines have been scorched from the face of the earth.

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Learning from the COVID-19 Policy Response

whitePaper | November 3, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic.

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Effects Of X-Ray Inspection On Pharmaceutical Products

whitePaper | December 12, 2019

X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.

More Whitepapers

The EU5 Market Access Landspace for Oncology Drugs